Patent · US Active

Fusion protein to target and treat acute myeloid leukemia cells

US10072093B2 · kind B2 · utility

0Cited by
5References
2Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJul 4, 2014
Grant dateSep 11, 2018
Priority date
Expiry dateJul 4, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y204/02036
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

A polypeptide which binds to the surface of AML blast cells and is internalized upon binding to the AML blast cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.